MedPath

ABBOTT INDIA LIMITED

🇮🇳India
Ownership
Private
Established
1888-01-01
Employees
73K
Market Cap
$7.5B
Website
http://www.abbott.com
Clinical Trials
Related News

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Phase 2
Completed
Conditions
Arthritis
Psoriatic
Interventions
Drug: adalimumab
Drug: placebo for adalimumab
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
315
Registration Number
NCT00646386

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

Phase 3
Completed
Conditions
End Stage Renal Disease
Interventions
Drug: paricalcitol capsules
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
75
Registration Number
NCT00646035

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: adalimumab
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
137
Registration Number
NCT00646191

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: placebo for adalimumab
Drug: adalimumab
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
148
Registration Number
NCT00645814

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

Phase 2
Completed
Conditions
Pediatric Epilepsy
Interventions
Drug: Depakote Delayed-Release/Depakote Sprinkle
Drug: Depakote ER
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
16
Registration Number
NCT00646711

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Phase 3
Completed
Conditions
Arthritis
Psoriatic
Interventions
Drug: placebo for adalimumab
Drug: adalimumab
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
102
Registration Number
NCT00646178

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: adalimumab
Drug: placebo for adalimumab
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
148
Registration Number
NCT00645905

Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects

Phase 3
Terminated
Conditions
Obesity
Weight Loss
Interventions
Drug: placebo
Drug: sibutramine or placebo
First Posted Date
2008-03-27
Last Posted Date
2008-03-27
Lead Sponsor
Abbott
Target Recruit Count
466
Registration Number
NCT00645255

Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

Phase 4
Completed
Conditions
Acute Bacterial Sinusitis
Interventions
Drug: cefdinir (Omnicef)
Drug: levofloxacin
First Posted Date
2008-03-27
Last Posted Date
2008-03-27
Lead Sponsor
Abbott
Target Recruit Count
271
Registration Number
NCT00645073

A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: cefdinir (Omnicef)
Drug: azithromycin
First Posted Date
2008-03-27
Last Posted Date
2008-03-27
Lead Sponsor
Abbott
Target Recruit Count
157
Registration Number
NCT00644774
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy